Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710722 · ClinicalTrials.gov registry record · NA
The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man
A NA study, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT01710722: Completed NA study, sponsored by Pennington Biomedical Research Center.
NCT01710722 is a NA study that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01710722, a NA study, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to compare three treatments to see which causes the most weight loss, fat loss, loss of stomach fat and improvement in blood tests like cholesterol.
Interventions
- DRUG caffeine and ephedrine
- DRUG Leptin A
- DRUG caffeine, ephedrine, and leptin A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2001-02 |
| Est. Completion | 2002-02 |
| Phase | NA |
What the finished NCT01710722 record still lists
NCT01710722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which caffeine and ephedrine is the first listed.
NCT01710722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01710722 about?
NCT01710722 is a clinical study titled "The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man". The purpose of this study is to compare three treatments to see which causes the most weight loss, fat loss, loss of stomach fat and improvement in blood tests like cholesterol.
What is the current status of trial NCT01710722?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2001-02. Estimated completion is 2002-02.
What interventions are being tested in trial NCT01710722?
The interventions under investigation include: caffeine and ephedrine (DRUG), Leptin A (DRUG), caffeine, ephedrine, and leptin A (DRUG).
Who is sponsoring clinical trial NCT01710722?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01710722's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia